tetano
Editor, Senior Moderator
Diabetes Res Clin Pract
. 2022 Dec 8;110205.
doi: 10.1016/j.diabres.2022.110205. Online ahead of print.
Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression
Hikmat Permana[SUP] 1 [/SUP], Theo Audi Yanto[SUP] 2 [/SUP], Timotius Ivan Hariyanto[SUP] 3 [/SUP]
Affiliations
Abstract
Aims: This study aims to examine the effectiveness of using sodium glucose transporter-2 inhibitor (SGLT-2i) before hospital admission on Covid-19 outcomes in diabetic patients.
Methods: A literature search was conducted using specific keywords until October 24th, 2022 on 4 databases: Medline, Scopus, Cochrane Library, and ClinicalTrials.gov. All articles regarding SGLT-2i in diabetic patients with Covid-19 were included in the study. Outcomes in this study were calculated using random-effect models to generate pooled odds ratio (OR) with 95% confidence intervals (CI).
Results: A total of 17 studies were included in the analysis. Our meta-analysis showed that pre-admission use of SGLT-2i was associated with reduced mortality (OR 0.69; 95%CI: 0.56 - 0.87, p=0.001, I[SUP]2[/SUP] = 91%) and severity of Covid-19 (OR 0.88; 95%CI: 0.80 - 0.97, p=0.008, I[SUP]2[/SUP] = 13%). This benefit of SGLT-2i on Covid-19 mortality was not significantly affected by patient's factors such as age (p=0.2335), sex (p=0.2742), hypertension (p=0.2165), heart failure (p=0.1616), HbA1c levels (p=0.4924), metformin use (p=0.6617), duration of diabetes (p=0.7233), and BMI (p=0.1797).
Conclusions: This study suggests that SGLT-2i as glucose lowering treatment in patients with diabetes has a positive effect on Covid-19 outcomes, therefore can be considered as an antidiabetic drug of choice, especially during the Covid-19 pandemic. Short Title: SGLT-2i in diabetes and Covid-19 Registration details: CRD42022369784.
Keywords: Covid-19; SGLT-2; antidiabetic; coronavirus disease 2019; diabetes.
. 2022 Dec 8;110205.
doi: 10.1016/j.diabres.2022.110205. Online ahead of print.
Pre-admission use of sodium glucose transporter-2 inhibitor (SGLT-2i) may significantly improves Covid-19 outcomes in patients with diabetes: A systematic review, meta-analysis, and meta-regression
Hikmat Permana[SUP] 1 [/SUP], Theo Audi Yanto[SUP] 2 [/SUP], Timotius Ivan Hariyanto[SUP] 3 [/SUP]
Affiliations
- PMID: 36502891
- DOI: 10.1016/j.diabres.2022.110205
Abstract
Aims: This study aims to examine the effectiveness of using sodium glucose transporter-2 inhibitor (SGLT-2i) before hospital admission on Covid-19 outcomes in diabetic patients.
Methods: A literature search was conducted using specific keywords until October 24th, 2022 on 4 databases: Medline, Scopus, Cochrane Library, and ClinicalTrials.gov. All articles regarding SGLT-2i in diabetic patients with Covid-19 were included in the study. Outcomes in this study were calculated using random-effect models to generate pooled odds ratio (OR) with 95% confidence intervals (CI).
Results: A total of 17 studies were included in the analysis. Our meta-analysis showed that pre-admission use of SGLT-2i was associated with reduced mortality (OR 0.69; 95%CI: 0.56 - 0.87, p=0.001, I[SUP]2[/SUP] = 91%) and severity of Covid-19 (OR 0.88; 95%CI: 0.80 - 0.97, p=0.008, I[SUP]2[/SUP] = 13%). This benefit of SGLT-2i on Covid-19 mortality was not significantly affected by patient's factors such as age (p=0.2335), sex (p=0.2742), hypertension (p=0.2165), heart failure (p=0.1616), HbA1c levels (p=0.4924), metformin use (p=0.6617), duration of diabetes (p=0.7233), and BMI (p=0.1797).
Conclusions: This study suggests that SGLT-2i as glucose lowering treatment in patients with diabetes has a positive effect on Covid-19 outcomes, therefore can be considered as an antidiabetic drug of choice, especially during the Covid-19 pandemic. Short Title: SGLT-2i in diabetes and Covid-19 Registration details: CRD42022369784.
Keywords: Covid-19; SGLT-2; antidiabetic; coronavirus disease 2019; diabetes.